Original Article
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
N Engl J Med 2008; 359:584-592August 7, 2008
- Abstract
Background
Fibroblast growth factor 23 (FGF-23) is a hormone that increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, thus helping to mitigate hyperphosphatemia in patients with kidney disease. Hyperphosphatemia and low 1,25-dihydroxyvitamin D levels are associated with mortality among patients with chronic kidney disease, but the effect of the level of FGF-23 on mortality is unknown.
Methods
We examined mortality according to serum phosphate levels in a prospective cohort of 10,044 patients who were beginning hemodialysis treatment and then analyzed FGF-23 levels and mortality in a nested case–control sample of 200 subjects who died and 200 who survived during the first year of hemodialysis treatment. We hypothesized that increased FGF-23 levels at the initiation of hemodialysis would be associated with increased mortality.
Results
Serum phosphate levels in the highest quartile (>5.5 mg per deciliter [1.8 mmol per liter]) were associated with a 20% increase in the multivariable adjusted risk of death, as compared with normal levels (3.5 to 4.5 mg per deciliter [1.1 to 1.4 mmol per liter]) (hazard ratio, 1.2; 95% confidence interval [CI], 1.1 to 1.4). Median C-terminal FGF-23 (cFGF-23) levels were significantly higher in case subjects than in controls (2260 vs. 1406 reference units per milliliter, P<0.001). Multivariable adjusted analyses showed that increasing FGF-23 levels were associated with a monotonically increasing risk of death when examined either on a continuous scale (odds ratio per unit increase in log-transformed cFGF-23 values, 1.8; 95% CI, 1.4 to 2.4) or in quartiles, with quartile 1 as the reference category (odds ratio for quartile 2, 1.6 [95% CI, 0.8 to 3.3]; for quartile 3, 4.5 [95% CI, 2.2 to 9.4]; and for quartile 4, 5.7 [95% CI, 2.6 to 12.6]).
Conclusions
Increased FGF-23 levels appear to be independently associated with mortality among patients who are beginning hemodialysis treatment. Future studies might investigate whether FGF-23 is a potential biomarker that can be used to guide strategies for the management of phosphorus balance in patients with chronic kidney disease.
Media in This Article
Figure 1
Odds Ratios (and 95% CIs) for Death According to Quartile of C-Terminal Fibroblast Growth Factor 23 (cFGF-23) Levels.Table 1
Characteristics of the ArMORR Cohort and the Nested Case–Control Sample at the Initiation of Hemodialysis.Article Activity
- Article
Fibroblast growth factor 23 (FGF-23), a hormone that is secreted by osteoblasts, is an important regulator of phosphorus and vitamin D metabolism. It was first described as a pathogenic factor in rare hypophosphatemic syndromes in which “primary” increases in biologically active FGF-23 cause renal phosphate wasting, hypophosphatemia, inappropriately low levels of 1,25-dihydroxyvitamin D, and rickets or osteomalacia.1-5 In contrast, depletion of FGF-23 leads to hyperphosphatemia, excessive levels of 1,25-dihydroxyvitamin D, ectopic calcification, and early death.6-8 Subsequent studies highlighted the physiologic role of FGF-23 in maintaining normal serum phosphate levels despite variability in dietary phosphorus intake.9,10
In patients with kidney disease, normal serum phosphate levels are maintained despite a declining nephron mass, in part by progressive “secondary” increases in FGF-23 levels, which stimulate greater excretion of phosphate through the remaining nephrons and limit the absorption of dietary phosphorus by inhibiting the synthesis of 1,25-dihydroxyvitamin D.11 Although increased levels of FGF-23 in patients with kidney disease are accompanied by certain features of primary excess of FGF-23, such as impaired bone mineralization and decreased 1,25-dihydroxyvitamin D levels,12,13 kidney disease is also complicated by hyperphosphatemia, ectopic calcification, and premature death, which are associated with the depletion of FGF-23.14,15 Thus, although increased serum phosphate levels and decreased 1,25-dihydroxyvitamin D levels are associated with increased mortality,12,16 it is unknown whether compensatory increases in FGF-23 secretion lead to or provide protection against death. We performed a prospective study involving patients in whom hemodialysis was being initiated, in order to test the hypothesis that increased FGF-23 levels are associated with increased mortality independently of established risk factors and contemporaneous serum phosphate measurements.
Methods
Study Overview
The Accelerated Mortality on Renal Replacement (ArMORR) study is a prospective cohort study of 10,044 subjects who began hemodialysis treatment at any of the 1056 U.S. dialysis centers operated by Fresenius Medical Care North America (Waltham, MA) in 2004 or 2005. All the subjects underwent 1 year of follow-up except for those who died (15%), underwent kidney transplantation (3%), recovered renal function (4%), or transferred to a dialysis unit outside the Fresenius Medical Care North America system before completing 1 year of hemodialysis treatment (12%).
All clinical data were prospectively collected by clinicians at the point of care. These data included demographic characteristics of the subjects, coexisting conditions, results of studies performed by a central laboratory (Spectra East, Northvale, NJ), and outcomes. Plasma and serum samples that were obtained at the initiation of outpatient hemodialysis and that would otherwise have been discarded after routine clinical testing were saved and stored in liquid nitrogen. Since coexisting conditions were ascertained at the initiation of dialysis, the frequencies of certain conditions are lower in the ArMORR database than in federal registries, which use data collected up to 90 days after the initiation of dialysis. The study was approved by the institutional review board of the Massachusetts General Hospital, which waived the need for informed consent from each patient because all personal identifiers were removed from the blood samples and from the clinical data before transfer to the investigators (see the Supplementary Appendix, available with the full text of this article at www.nejm.org).
Study Population
We first examined mortality according to the baseline serum phosphate level in the entire ArMORR cohort and then analyzed the relation between the baseline FGF-23 level and mortality in a nested case–control sample, defining case subjects as those who died during the first year of hemodialysis treatment and controls as those who survived. On the basis of pilot data, we estimated that 50 case subjects and 50 controls would provide 90% power to detect a standardized difference of 0.66 in mean FGF-23 levels, assuming a two-sided type I error rate of 5%. Hyperphosphatemia is a risk factor for death16 that is correlated with the FGF-23 level.11 To minimize potential confounding effects of serum phosphate levels, we used frequency matching to randomly select 50 cases and 50 controls from the ArMORR cohort within each quartile of baseline serum phosphate levels. The final sample of 200 case subjects and 200 controls provided 90% power to detect an odds ratio for death of 1.8 for the highest FGF-23 quartile as compared with the lowest, with a two-sided type I error rate of 5%.
The main stimuli for the secretion of FGF-23 are increased dietary intake of phosphorus and activated vitamin D,9,10,17 which has been associated with improved survival among patients undergoing hemodialysis.18-21 Thus, increased FGF-23 levels in unselected patients could reflect high phosphorus exposure (a risk factor), previous therapy with activated vitamin D (a protective factor), or both. Therefore, we excluded subjects whose therapy with activated vitamin D was initiated before their baseline blood sample was obtained. Subjects remained eligible if they received activated vitamin D after the baseline measurements were obtained, and activated vitamin D was analyzed as a covariate. We excluded from the main analyses subjects who had less than 1 year of follow-up because they underwent kidney transplantation, recovered kidney function, or transferred to a dialysis center outside the Fresenius Medical Care North America system (19% of the subjects). To ensure that the 200 controls selected for the analysis were representative of all possible controls under the risk-set sampling theory, we measured FGF-23 levels in an additional random sample of 50 of the excluded subjects who were alive at the time the case subjects died.
Blacks and Hispanics are at a greater risk for end-stage renal disease than non-Hispanic whites but have a significant survival advantage when they begin undergoing dialysis.22-25 Since there are no data on FGF-23 levels according to race or ethnic group or on the effect of FGF-23 levels on survival, we focused on black, Hispanic, and non-Hispanic white subjects and excluded subjects of other races (6%).
Exposures, Outcomes, and Covariates
The primary exposure variable was the baseline plasma FGF-23 level, measured at the initiation of outpatient hemodialysis. The primary outcome was 1-year, all-cause mortality. FGF-23 levels were measured in duplicate after a single freeze–thaw cycle in batched assays by an investigator who was unaware of the outcomes. Although C-terminal FGF-23 (cFGF-23) fragments accumulate in patients with kidney disease,26 few studies of patients with renal failure have directly compared the results from cFGF-23 assays, which detect both intact FGF-23 (iFGF-23) and its C-terminal fragments, with iFGF-23 assays, which are specific for the intact molecule. Therefore, we measured both cFGF-23 and iFGF-23 (Immutopics) (interassay and intraassay coefficients of variation, <5% for each). Serum was available for radioimmunoassay of 1,25-dihydroxyvitamin D levels (DiaSorin) in 52 case subjects and 69 controls. Serum phosphate was measured with the use of standard assays, and 1-84 parathyroid hormone was measured with the use of a Nichols Bio-Intact assay.
Statistical Analysis
We used descriptive statistics to compare baseline demographic characteristics and the results of laboratory tests in the overall ArMORR cohort, among case subjects and controls, and according to race or ethnic group. We used a Spearman correlation analysis to test the association between cFGF-23 and iFGF-23. To test for nonlinear associations between FGF-23 and mortality, we examined FGF-23 levels in quartiles according to the distribution of values in the overall sample. We performed parallel analyses of cFGF-23 and iFGF-23.
We used a Cox proportional-hazards analysis to examine the risk of death associated with baseline phosphate levels in the full ArMORR cohort, censoring the data at the time a patient underwent kidney transplantation, transferred to a dialysis center outside the Fresenius Medical Care North America system, or recovered kidney function. We used logistic regression to test the association between FGF-23 levels and mortality in the case–control sample. Multivariable models were used to adjust for confounding. All analyses were prespecified except the post hoc analysis of the 50 additional controls. In the multivariable models, we adjusted for baseline laboratory values and the following case-mix variables: age, sex, race, ethnic group, cause of renal failure, blood pressure, body-mass index, coexisting conditions, vascular access at initiation of dialysis (fistula, graft, or catheter), urea reduction ratio, and facility-specific standardized mortality rates. We included variables in the multivariable models that in previous studies have been associated with the risk of death in people undergoing hemodialysis, as well as variables that differed significantly between case subjects and controls.
Results of laboratory tests were analyzed on a continuous scale; non-normal variables were log-transformed. Since treatment with dietary phosphorus binders can reduce FGF-23 levels,27,28 we further adjusted for the use of phosphorus binders that preceded the FGF-23 measurements and conducted a prespecified subgroup analysis that excluded subjects who had received previous treatment with binders. We also adjusted for subsequent treatment with activated vitamin D. To test the robustness of the results with various analytic strategies, we examined models using forward, backward, and stepwise selection procedures; assessed goodness-of-fit with the use of the Hosmer–Lemeshow statistic; and tested for overfitting with the bootstrap technique. We formally tested for an interaction between the FGF-23 level and race or ethnic group by including interaction terms for black race and FGF-23 level and for Hispanic ethnic group and FGF-23 level, and when the results were significant, we analyzed stratified models. Analyses were performed with the use of Intercooled Stata software, version 7.0. Two-sided P values of less than 0.05, unadjusted for multiple testing, were considered to indicate statistical significance. All data were collected and analyzed by the ArMORR investigators.
Results
Serum Phosphate Levels and Mortality
The characteristics of the 10,044 ArMORR participants and the nested case–control sample at the initiation of hemodialysis are shown in Table 1Table 1
Characteristics of the ArMORR Cohort and the Nested Case–Control Sample at the Initiation of Hemodialysis.. The mean (±SD) serum phosphate level, 4.6±1.6 mg per deciliter (1.49±0.52 mmol per liter), was lower than that in previous studies of patients undergoing hemodialysis; otherwise, baseline characteristics were similar to those in previous reports. After multivariable adjustment, serum phosphate levels greater than 5.5 mg per deciliter (highest quartile) were associated with an increased risk of death as compared with levels of 3.5 to 4.5 mg per deciliter (hazard ratio, 1.2; 95% confidence interval [CI], 1.1 to 1.4). This finding is consistent with the findings in previous studies.20 FGF-23 Levels and Mortality
There was a strong linear correlation between the cFGF-23 levels (median, 1752 reference units [RU] per milliliter; interquartile range, 1089 to 4019) and iFGF-23 levels (median, 713 pg per milliliter; interquartile range, 579 to 951) (r=0.74, P<0.001) (Fig. 1 in the Supplementary Appendix). All subsequent results were qualitatively similar for cFGF-23 and iFGF-23; therefore, only the results for cFGF-23 are reported here (see the Supplementary Appendix for iFGF-23 results). Results of laboratory tests according to quartiles of cFGF-23 levels are shown in Table 2Table 2
Laboratory Results and Use or Nonuse of Phosphorus Binders, According to Quartiles of cFGF-23 Level..The median cFGF-23 level was significantly higher in patients who died than in those who survived, in the overall sample and within each quartile of serum phosphate levels except the highest, in which the comparison did not reach significance (Table 3Table 3
Levels of cFGF-23 and Associated Risk of Death within Serum Phosphate Quartiles in the Case–Control Sample.). In univariate analyses, an increased cFGF-23 level was associated with an increased risk of death in the overall population (odds ratio per unit increase in the natural log-transformed cFGF-23 value, 1.5; 95% CI, 1.2 to 1.8) and in each serum phosphate quartile except the highest (Table 3) (P=0.26 for an interaction). The FGF-23 level remained significantly associated with the risk of death when the analysis was adjusted for case-mix variables (odds ratio per unit increase in the log cFGF-23 value, 1.6; 95% CI, 1.2 to 1.9) and for results of laboratory tests (odds ratio per unit increase in the log cFGF-23 value, 1.8; 95% CI, 1.4 to 2.4). The results were qualitatively unchanged when different model-building strategies were used and when the models were further adjusted for the 1,25-dihydroxyvitamin D level, analyzed in categories, with a separate category for missing values, or when multiple imputation was used (data not shown). The final multivariable adjusted model was reliable (P=0.98 by the Hosmer–Lemeshow test); evaluation with the bootstrap technique showed that the results were not overfitted to the data set.When FGF-23 levels were examined in quartiles, there was a monotonic increase in mortality with increasing cFGF-23 levels in univariate, case-mix adjusted, and fully adjusted models (Figure 1Figure 1
Odds Ratios (and 95% CIs) for Death According to Quartile of C-Terminal Fibroblast Growth Factor 23 (cFGF-23) Levels.). In addition, the results were qualitatively unchanged when the analysis was further adjusted for subsequent therapy with activated vitamin D and for prior therapy with phosphorus binders and when subjects who had previously been treated with binders were excluded (data not shown), as well as in post hoc analyses that included the 50 additional controls (see the Supplementary Appendix).Interaction with Race or Ethnic Group
Black and Hispanic patients had a significant survival advantage as compared with whites in the full ArMORR cohort and in the case–control sample (odds ratio for blacks, 0.5 [95% CI, 0.3 to 0.8], and odds ratio for Hispanics, 0.4 [95% CI, 0.2 to 0.7]); this finding is consistent with the results of previous studies involving patients undergoing hemodialysis.12,24,25,29 Although there were no significant differences in phosphate levels according to race or ethnic group, the median FGF-23 level was significantly lower among blacks (1579 RU per milliliter; interquartile range, 966 to 2959) and Hispanics (1336 RU per milliliter; interquartile range, 1094 to 2262), than among whites (2016 RU per milliliter; interquartile range, 1132 to 4865) (P=0.02 and P=0.04, respectively). Although there was no significant interaction among ethnic group, FGF-23 levels, and mortality, there was a significant interaction with race (P=0.048). As compared with whites who had cFGF-23 levels below the population median, blacks who had cFGF-23 levels below the median had a 60% lower risk of death (odds ratio, 0.4; 95% CI, 0.2 to 0.7), whereas the risk of death was similar for blacks and whites who had cFGF-23 levels above the median (odds ratio, 1.3 [95% CI, 0.7 to 2.3] and 1.6 [95% CI, 0.97 to 2.5], respectively).
Discussion
In this prospective study of patients who were beginning hemodialysis treatment, increased FGF-23 levels were associated with mortality independently of serum phosphate levels and other known risk factors. The results were virtually identical with the use of two different FGF-23 assays and showed a strong dose–response relationship. The magnitude of the risk associated with increasing FGF-23 quartiles was substantially larger than the analogous results for serum phosphate quartiles in the overall cohort. In addition, differences according to race were apparent. Further studies are needed to determine whether strategies for the control of phosphorus homeostasis that are guided by FGF-23 measurements might benefit patients with kidney disease who have normal serum phosphate levels — patients for whom these therapies are not routinely recommended but for whom they may be of substantial clinical benefit.
Patients with renal failure have severe vascular disease and are at risk for premature death in association with hyperphosphatemia and 1,25-dihydroxyvitamin D deficiency,12 but several observational studies suggest that for patients who are undergoing hemodialysis, therapy with activated vitamin D provides a survival benefit that is independent of the serum phosphate level.18-21 FGF-23–knockout mice are characterized by hyperphosphatemia, 1,25-dihydroxyvitamin D intoxication, and metastatic vascular calcification, resulting in early death. These phenotypic features of FGF-23–knockout mice can be attenuated by ablation of 25-hydroxyvitamin D-1α-hydroxylase, suggesting that excessive 1,25-dihydroxyvitamin D levels in combination with hyperphosphatemia may be harmful.30 Indeed, the maintenance of FGF-23–knockout mice on a diet deficient in vitamin D prolongs their survival despite persistent hyperphosphatemia.8 Thus, whereas the depletion of FGF-23 and an excess of 1,25-dihydroxyvitamin D are associated with increased mortality in the relevant animal models with normal renal function, an excess of FGF-23 and a deficiency of 1,25-dihydroxyvitamin D appear to be associated with increased mortality in humans with renal failure. These discrepant results highlight the need for carefully designed studies in humans with kidney disease. We aimed to minimize confounding by excluding patients who had previously been treated with activated vitamin D. Although this limits our ability to generalize the results to all patients who are undergoing hemodialysis, it would be inappropriate to cite the present study as evidence of the potential toxicity of activated vitamin D through increased FGF-23 levels.
Previous studies of FGF-23 were conduct-ed among mostly white and Asian popula-tions.9-11,26,31 None of those studies compared levels across races, and none reported levels among blacks and Hispanics. We found that FGF-23 levels were 22% and 34% lower in blacks and Hispanics, respectively, than in whites. This finding is not surprising when it is interpreted in the context of other racial differences in mineral metabolism. For example, blacks have decreased urinary phosphate excretion and increased serum phosphate levels as compared with whites, despite increased parathyroid hormone levels.32-34 Decreased FGF-23 expression could account for this discrepancy. Along with increased parathyroid hormone levels, decreased FGF-23 levels could also account for higher 1,25-dihydroxyvitamin D levels among blacks than among whites, despite the fact that blacks have lower levels of 25-dihydroxyvitamin D, which is the metabolic precursor of 1,25-dihydroxyvitamin D.32 One might speculate that decreased FGF-23 levels among blacks could represent an adaptation to maintain normal bone mineralization in the face of high rates of vitamin D deficiency and secondary hyperparathyroidism. The question of whether decreased FGF-23 levels might contribute to the well-known but poorly understood survival advantage of blacks who are undergoing dialysis is also intriguing. Support for this possibility is provided by our findings that blacks had significantly lower FGF-23 levels than whites and that among subjects with lower FGF-23 levels, blacks had a significantly decreased risk of death as compared with whites.
A limitation of this study is that we were unable to determine whether increased FGF-23 levels are directly toxic or are a surrogate marker of the toxicity of other factors. It is possible that at the extremely high concentrations we observed, FGF-23 binds FGF receptors with sufficiently high affinity, even in the absence of its coreceptor Klotho, to stimulate the production of factors that have been implicated in the development of vascular disease but that are normally generated in response to basic FGF.35 Alternatively, increased FGF-23 levels may reflect toxicity that is due to prolonged exposure to a high dietary intake of phosphorus, which has been associated with adverse outcomes in patients with kidney disease but which we were unable to quantify in this study. Additional research is needed to explore these possibilities. Other potential limitations include residual confounding by coexisting conditions that were not ascertained, misclassification of vitamin D treatment, and the restriction to 1-year outcomes.
The 20% increased risk of death that we observed among patients in the highest quartile of phosphate levels was similar to the risk in previous reports.16 Similarly, serum phosphate levels greater than 3.5 mg per deciliter were associated with approximately a 28% increase in the risk of death in studies involving patients with early stages of kidney disease or patients without kidney disease.36,37 In contrast, we found a monotonic, dose–response relationship between FGF-23 levels and mortality, such that subjects in the highest quartile of FGF-23 levels had nearly a 600% increase in risk as compared with subjects in the lowest quartile. These results suggest that serum phosphate levels, which are influenced by dietary intake, phosphorus binders, urinary and dialysis clearance, and bone and soft-tissue deposition, provide only a partial assessment of the risk associated with abnormal phosphorus metabolism, especially when the levels are normal. In comparison, FGF-23 levels were most informative when serum phosphate levels were relatively low. Thus, FGF-23 could represent a new biomarker for assessing the risk of death that may be especially useful in patients with early kidney disease, in whom FGF-23 levels increase long before hyperphosphatemia first develops11 but who already have a markedly increased risk of death.38 Currently, the vast majority of the estimated 20 million people with chronic kidney disease in the United States are neither advised to restrict dietary phosphorus nor treated with dietary phosphorus binders, which lower FGF-23 levels in a dose–response fashion.9,10,27,28 The results of the current study suggest that FGF-23 measurements may be a sensitive tool to identify which of those patients who have normal serum phosphate levels might benefit from the use of such strategies to manage phosphorus balance.
Supported by the American Kidney Fund Clinical Scientist in Nephrology Fellowship (to Dr. Gutiérrez) and by grants from the American Society of Nephrology–Alaska Kidney Foundation (to Dr. Wolf), the Center for D-Receptor Activation Research at the Massachusetts General Hospital, and the National Institutes of Health (K30RR02229207; R21DK071674, to Dr. Thadhani; K23RR017376, to Dr. Wolf; and RO1DK076116, to Dr. Wolf).
Dr. Jüppner reports holding an active patent on the C-terminal FGF-23 assay manufactured by Immutopics. Dr. Wolf reports having a pending patent application on FGF-23 measurements as a diagnostic aid and receiving consulting and lecture fees from Abbott, Genzyme, and INEOS and grant support from Shire. Dr. Thadhani reports receiving consulting and lecture fees from Abbott and Genzyme and grant support from Abbott. No other potential conflict of interest relevant to this article was reported.
Drs. Gutiérrez and Mannstadt contributed equally to this article.
Source Information
From the Renal Unit (O.M.G., T.I., J.A.R.-H., H.T., A.S., K.S., R.T., M.W.), Endocrine Unit (M.M., H.J.), and Biostatistics Center (H.L.), Department of Medicine, and the Pediatric Nephrology Unit, Department of Pediatrics (H.J.), Massachusetts General Hospital and Harvard Medical School, Boston.
Address reprint requests to Dr. Wolf at the Division of Nephrology and Hypertension, University of Miami, Miller School of Medicine, 1120 NW 14th St., Miami, FL 33136, or at mwolf2@med.miami.edu.
- References
References
1
Jonsson KB ,Zahradnik R ,Larsson T , et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-1663
Full Text | Web of Science | Medline2
White KE ,Jonsson KB ,Carn G , et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001;86:497-500
CrossRef | Web of Science | Medline3
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-348
CrossRef | Web of Science | Medline4
Shimada T ,Mizutani S ,Muto T , et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001;98:6500-6505
CrossRef | Web of Science | Medline5
De Beur SM ,Finnegan RB ,Vassiliadis J , et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 2002;17:1102-1110
CrossRef | Web of Science | Medline6
Shimada T ,Kakitani M ,Yamazaki Y , et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-568
CrossRef | Web of Science | Medline7
Benet-Pages A ,Orlik P ,Strom TM ,Lorenz-Depiereux B . An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005;14:385-390
CrossRef | Web of Science | Medline8
Stubbs JR ,Liu S ,Tang W , et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007;18:2116-2124
CrossRef | Web of Science | Medline9
Antoniucci DM ,Yamashita T ,Portale AA . Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006;91:3144-3149
CrossRef | Web of Science | Medline10
Burnett SM ,Gunawardene SC ,Bringhurst FR ,Juppner H ,Lee H ,Finkelstein JS . Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006;21:1187-1196
CrossRef | Web of Science | Medline11
Gutierrez O ,Isakova T ,Rhee E , et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205-2215
CrossRef | Web of Science | Medline12
Wolf M ,Shah A ,Gutierrez O , et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004-1013
CrossRef | Web of Science | Medline13
Ritz E ,Krempien B ,Mehls O ,Malluche H . Skeletal abnormalities in chronic renal insufficiency before and during maintenance hemodialysis. Kidney Int 1973;4:116-127
CrossRef | Web of Science | Medline14
Cozzolino M ,Brancaccio D ,Gallieni M ,Slatopolsky E . Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429-436
CrossRef | Web of Science | Medline15
Ben-Dov IZ ,Galitzer H ,Lavi-Moshayoff V , et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-4008
Web of Science | Medline16
Block GA ,Klassen PS ,Lazarus JM ,Ofsthun N ,Lowrie EG ,Chertow GM . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218
CrossRef | Web of Science | Medline17
Saito H ,Maeda A ,Ohtomo S , et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005;280:2543-2549
CrossRef | Web of Science | Medline18
Teng M ,Wolf M ,Lowrie E ,Ofsthun N ,Lazarus JM ,Thadhani R . Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456
Full Text | Web of Science | Medline19
Teng M ,Wolf M ,Ofsthun MN , et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-1125
CrossRef | Web of Science | Medline20
Kalantar-Zadeh K ,Kuwae N ,Regidor DL , et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-780
CrossRef | Web of Science | Medline21
Melamed ML ,Eustace JA ,Plantinga L , et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006;70:351-357
CrossRef | Web of Science | Medline22
U.S. Renal Data System. USRDS 2003 annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004.
23
Cowie CC ,Port FK ,Wolfe RA ,Savage PJ ,Moll PP ,Hawthorne VM . Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989;321:1074-1079
Full Text | Web of Science | Medline24
Robinson BM ,Joffe MM ,Pisoni RL ,Port FK ,Feldman HI . Revisiting survival differences by race and ethnicity among hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 2006;17:2910-2918
CrossRef | Web of Science | Medline25
Frankenfield DL ,Rocco MV ,Roman SH ,McClellan WM . Survival advantage for adult Hispanic hemodialysis patients? Findings from the End-Stage Renal Disease Clinical Performance Measures Project. J Am Soc Nephrol 2003;14:180-186
CrossRef | Web of Science | Medline26
Larsson T ,Nisbeth U ,Ljunggren O ,Juppner H ,Jonsson KB . Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-2279
CrossRef | Web of Science | Medline27
Nagano N ,Miyata S ,Abe M , et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006;69:531-537
CrossRef | Web of Science | Medline28
Koiwa F ,Kazama JJ ,Tokumoto A , et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005;9:336-339
CrossRef | Web of Science | Medline29
Wolf M ,Betancourt J ,Chang Y , et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008;19:1379-1388
CrossRef | Web of Science | Medline30
Sitara D ,Razzaque MS ,St-Arnaud R , et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 2006;169:2161-2170
CrossRef | Web of Science | Medline31
Shigematsu T ,Kazama JJ ,Yamashita T , et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004;44:250-256
CrossRef | Web of Science | Medline32
Bell NH ,Greene A ,Epstein S ,Oexmann MJ ,Shaw S ,Shary J . Evidence for alteration of the vitamin D-endocrine system in blacks. J Clin Invest 1985;76:470-473
CrossRef | Web of Science | Medline33
Foley RN ,Wang C ,Ishani A ,Collins AJ . NHANES III: influence of race on GFR thresholds and detection of metabolic abnormalities. J Am Soc Nephrol 2007;18:2575-2582
CrossRef | Web of Science | Medline34
Gutierrez OM ,Isakova T ,Andress DL ,Levin A ,Wolf M . Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int 2008;73:956-962
CrossRef | Web of Science | Medline35
Yu X ,Ibrahimi OA ,Goetz R , et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005;146:4647-4656
CrossRef | Web of Science | Medline36
Kestenbaum B ,Sampson JN ,Rudser KD , et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528
CrossRef | Web of Science | Medline37
Tonelli M ,Sacks F ,Pfeffer M ,Gao Z ,Curhan G . Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-2633[Erratum, Circulation 2007;116:3556.]
CrossRef | Web of Science | Medline38
Go AS ,Chertow GM ,Fan D ,McCulloch CE ,Hsu CY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305
Full Text | Web of Science | Medline
- Citing Articles (189)
Citing Articles
1
Justine Bacchetta, Pierre Cochat, Isidro B Salusky, Katherine Wesseling-Perry. (2012) Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function. Pediatric Nephrology
CrossRef2
Mahmut Ilker Yilmaz, Alper Sonmez, Mutlu Saglam, Halil Yaman, Selim Kilic, Tayfun Eyileten, Kayser Caglar, Yusuf Oguz, Abdulgaffar Vural, Mujdat Yenicesu, Francesca Mallamaci, Carmine Zoccali. (2012) Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial. American Journal of Kidney Diseases 59:2, 177-185
CrossRef3
L. Darryl Quarles. (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nature Reviews Endocrinology
CrossRef4
Giuseppe Maltese, Janaka Karalliedde. (2012) The Putative Role of the Antiageing Protein Klotho in Cardiovascular and Renal Disease. International Journal of Hypertension 2012, 1-5
CrossRef5
Giacomo Zoppellaro, Elisabetta Faggin, Massimo Puato, Paolo Pauletto, Marcello Rattazzi. (2012) Fibroblast Growth Factor 23 and the Bone-Vascular Axis: Lessons Learned From Animal Studies. American Journal of Kidney Diseases 59:1, 135-144
CrossRef6
Jason R Stubbs, Nan He, Arun Idiculla, Ryan Gillihan, Shiguang Liu, Valentin David, Yan Hong, L Darryl Quarles. (2012) Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. Journal of Bone and Mineral Research 27:1, 38-46
CrossRef7
Orlando M. Gutiérrez, Ronit Katz, Carmen A. Peralta, Ian H. de Boer, David Siscovick, Myles Wolf, Ana Diez Roux, Bryan Kestenbaum, Jennifer A. Nettleton, Joachim H. Ix. (2012) Associations of Socioeconomic Status and Processed Food Intake With Serum Phosphorus Concentration in Community-Living Adults: The Multi-Ethnic Study of Atherosclerosis (MESA). Journal of Renal Nutrition
CrossRef8
Jochen G. Raimann, Stephan Thijssen, Nathan W. Levin. (2012) A Brief Review of External Mass Balance and Internal Calcium Redistribution in Dialysis Patients—Is Calcium a Uremic Toxin?. Journal of Renal Nutrition 22:1, 186-190
CrossRef9
Tomasz Hryszko, Alicja Rydzewska-Rosolowska, Szymon Brzosko, Ewa Koc-Zorawska, Michal Mysliwiec. (2012) Low Molecular Weight Iron Dextran Increases Fibroblast Growth Factor-23 Concentration, Together With PTH Decrease in Hemodialyzed Patients. Therapeutic Apheresis and Dialysisno-no
CrossRef10
Timothy V. Nguyen, Amy Wang. (2012) Hyperphosphatemia: Consequences and Management Strategies. The Journal for Nurse Practitioners 8:1, 56-60
CrossRef11
Katherine Wesseling Perry, Isidro B. Salusky. 2012. Chronic Kidney Disease Mineral and Bone Disorder. , 795-820.
CrossRef12
Max Plischke, Stephanie Neuhold, Christopher Adlbrecht, Bernhard Bielesz, Sascha Shayganfar, Christian Bieglmayer, Thomas Szekeres, Walter H. Hörl, Guido Strunk, Patrick Vavken, Richard Pacher, Martin Hülsmann. (2011) Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. European Journal of Clinical Investigationno-no
CrossRef13
Fellype Carvalho Barreto, Rodrigo Azevedo de Oliveira, Rodrigo Bueno Oliveira, Vanda Jorgetti. (2011) Pharmacotherapy of chronic kidney disease and mineral bone disorder. Expert Opinion on Pharmacotherapy 12:17, 2627-2640
CrossRef14
Katherine Wesseling-Perry, Justine Bacchetta. (2011) CKD-MBD after kidney transplantation. Pediatric Nephrology 26:12, 2143-2151
CrossRef15
Wei-Xia Jian, Wen-Hui Peng, Jie Jin, Xue-Ru Chen, Wen-Jun Fang, Wei-Xing Wang, Li Qin, Yan Dong, Qing Su. (2011) Association between serum fibroblast growth factor 21 and diabetic nephropathy. Metabolism
CrossRef16
D. Hansen, K. Rasmussen, S. M. Pedersen, L. M. Rasmussen, L. Brandi. (2011) Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrology Dialysis Transplantation
CrossRef17
Navdeep Tangri, Andrew S. Levey. (2011) Fibroblast Growth Factor 23 and CKD Prognosis. American Journal of Kidney Diseases
CrossRef18
Armin Zittermann, Uwe Fuchs, Joachim Kuhn, Jens Dreier, Uwe Schulz, Jan F. Gummert, Jochen Börgermann. (2011) Parameters of Mineral Metabolism predict Midterm Clinical Outcome in End-Stage Heart Failure Patients. Scandinavian Cardiovascular Journal 45:6, 342-348
CrossRef19
, L. Desjardins, S. Liabeuf, C. Renard, A. Lenglet, H.-D. Lemke, G. Choukroun, T. B. Drueke, Z. A. Massy. (2011) FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporosis International
CrossRef20
Lavinia A. Negrea. (2011) Biochemical Abnormalities in Chronic Kidney Disease–Mineral Bone Disease. Clinical Reviews in Bone and Mineral Metabolism
CrossRef21
Christian Faul, Ansel P. Amaral, Behzad Oskouei, Ming-Chang Hu, Alexis Sloan, Tamara Isakova, Orlando M. Gutiérrez, Robier Aguillon-Prada, Joy Lincoln, Joshua M. Hare, Peter Mundel, Azorides Morales, Julia Scialla, Michael Fischer, Elsayed Z. Soliman, Jing Chen, Alan S. Go, Sylvia E. Rosas, Lisa Nessel, Raymond R. Townsend, Harold I. Feldman, Martin St. John Sutton, Akinlolu Ojo, Crystal Gadegbeku, Giovana Seno Di Marco, Stefan Reuter, Dominik Kentrup, Klaus Tiemann, Marcus Brand, Joseph A. Hill, Orson W. Moe, Makoto Kuro-o, John W. Kusek, Martin G. Keane, Myles Wolf. (2011) FGF23 induces left ventricular hypertrophy. Journal of Clinical Investigation 121:11, 4393-4408
CrossRef22
Rachel M. Holden, David Beseau, Sarah L. Booth, Michael A. Adams, Jocelyn S. Garland, Ross A. Morton, Christine P. Collier, Robert N. Foley. (2011) FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. Hemodialysis Internationaln/a-n/a
CrossRef23
S. Seiler, B. Cremers, N. M. Rebling, F. Hornof, J. Jeken, S. Kersting, C. Steimle, P. Ege, M. Fehrenz, K. S. Rogacev, B. Scheller, M. Bohm, D. Fliser, G. H. Heine. (2011) The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. European Heart Journal 32:21, 2688-2696
CrossRef24
M. Dalal, K. Sun, A. R. Cappola, L. Ferrucci, C. Crasto, L. P. Fried, R. D. Semba. (2011) Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. European Journal of Endocrinology 165:5, 797-803
CrossRef25
Jessica Kendrick, Michel Chonchol. (2011) The Role of Phosphorus in the Development and Progression of Vascular Calcification. American Journal of Kidney Diseases 58:5, 826-834
CrossRef26
Alberto Ortiz, Ziad A. Massy, Danilo Fliser, Bengt Lindholm, Andrzej Wiecek, Alberto Martínez-Castelao, Adrian Covic, David Goldsmith, Gültekin Süleymanlar, Gérard M. London, Carmine Zoccali. (2011) Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nature Reviews Nephrology
CrossRef27
L. Viaene, B. Bammens, B. K. I. Meijers, Y. Vanrenterghem, D. Vanderschueren, P. Evenepoel. (2011) Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrology Dialysis Transplantation
CrossRef28
Kraiwiporn Kiattisunthorn, Sharon M. Moe. (2011) Chronic Kidney Disease-Mineral Bone Disorder: Definitions and Rationale for a Systemic Disorder. Clinical Reviews in Bone and Mineral Metabolism
CrossRef29
Emily G. Farrow, Erik A. Imel, Kenneth E. White. (2011) Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho). Best Practice & Research Clinical Rheumatology 25:5, 735-747
CrossRef30
Claus Peter Schmitt, Otto Mehls. (2011) Mineral and bone disorders in children with chronic kidney disease. Nature Reviews Nephrology 7:11, 624-634
CrossRef31
M. Ketteler, K. J. Martin, M. Cozzolino, D. Goldsmith, A. Sharma, S. Khan, E. Dumas, M. Amdahl, S. Marx, P. Audhya. (2011) Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrology Dialysis Transplantation
CrossRef32
Yuichiro Shimizu, Seiji Fukumoto, Toshiro Fujita. (2011) Evaluation of a new automated chemiluminescence immunoassay for FGF23. Journal of Bone and Mineral Metabolism
CrossRef33
Alastair J. Hutchison, Craig P. Smith, Paul E. C. Brenchley. (2011) Pharmacology, efficacy and safety of oral phosphate binders. Nature Reviews Nephrology 7:10, 578-589
CrossRef34
Marc G Vervloet, Tobias E Larsson. (2011) Fibroblast growth factor-23 and Klotho in chronic kidney disease. Kidney International Supplements 1:4, 130-135
CrossRef35
Charles A Herzog, Richard W Asinger, Alan K Berger, David M Charytan, Javier Díez, Robert G Hart, Kai-Uwe Eckardt, Bertram L Kasiske, Peter A McCullough, Rod S Passman, Stephanie S DeLoach, Patrick H Pun, Eberhard Ritz. (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 80:6, 572-586
CrossRef36
Ignacio López, M Encarnación Rodríguez-Ortiz, Yolanda Almadén, Fátima Guerrero, A Montes de Oca, Carmen Pineda, Vicky Shalhoub, Mariano Rodríguez, Escolástico Aguilera-Tejero. (2011) Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney International 80:5, 475-482
CrossRef37
Seiji Fukumoto, Yuichiro Shimizu. (2011) Fibroblast growth factor 23 as a phosphotropic hormone and beyond. Journal of Bone and Mineral Metabolism 29:5, 507-514
CrossRef38
Javier Donate-Correa, Carmen Mora-Fernández, Rafael Martínez-Sanz, Mercedes Muros-de-Fuentes, Horacio Pérez, Beatriz Meneses-Pérez, Violeta Cazaña-Pérez, Juan F. Navarro-González. (2011) Expression of FGF23/KLOTHO system in human vascular tissue. International Journal of Cardiology
CrossRef39
Tomasz Hryszko, Szymon Brzosko, Alicja Rydzewska-Rosolowska, Ewa Koc-Zorawska, Michal Mysliwiec. (2011) Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. International Urology and Nephrology
CrossRef40
M. R. Custodio, M. K. Koike, K. R. Neves, L. M. dos Reis, F. G. Graciolli, C. L. Neves, D. G. Batista, A. O. Magalhaes, P. Hawlitschek, I. B. Oliveira, W. V. Dominguez, R. M. A. Moyses, V. Jorgetti. (2011) Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrology Dialysis Transplantation
CrossRef41
M. A. Murtaugh, R. Filipowicz, B. C. Baird, G. Wei, T. Greene, S. Beddhu. (2011) Dietary phosphorus intake and mortality in moderate chronic kidney disease: NHANES III. Nephrology Dialysis Transplantation
CrossRef42
J. Bernheim, S. Benchetrit. (2011) The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrology Dialysis Transplantation 26:8, 2433-2438
CrossRef43
E. Gonzalez-Parra, M. L. Gonzalez-Casaus, A. Galan, A. Martinez-Calero, V. Navas, M. Rodriguez, A. Ortiz. (2011) Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrology Dialysis Transplantation 26:8, 2567-2571
CrossRef44
Lauren Martz. (2011) Marked for ESRD. Science-Business eXchange 4:28,
CrossRef45
T. Shigematsu, S. Negi, . (2011) Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study). Nephrology Dialysis Transplantation
CrossRef46
M. L. Ford, E. R. Smith, L. A. Tomlinson, P. K. Chatterjee, C. Rajkumar, S. G. Holt. (2011) FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrology Dialysis Transplantation
CrossRef47
M. Koizumi, H. Komaba, S. Nakanishi, A. Fujimori, M. Fukagawa. (2011) Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation
CrossRef48
Yun Chau Long, Alexei Kharitonenkov. (2011) Hormone-like fibroblast growth factors and metabolic regulation. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812:7, 791-795
CrossRef49
María Luisa González Casaús, Emilio González Parra, Víctor Manuel Navas Serrano, Carolina Gracia Iguacel, Pilar de Ribera Pieras, Jesús Egido de Los Ríos. (2011) Tratamiento de la hiperfosfatemia asociada a la enfermedad renal crónica con carbonato de lantano. Nuevas evidencias. Diálisis y Trasplante 32:3, 102-107
CrossRef50
George B. John, Chung-Yi Cheng, Makoto Kuro-o. (2011) Role of Klotho in Aging, Phosphate Metabolism, and CKD. American Journal of Kidney Diseases 58:1, 127-134
CrossRef51
Werner Ribitsch, Alexander R Rosenkranz. (2011) Prehypertension and prechronic kidney disease: fact or fiction?. Expert Review of Cardiovascular Therapy 9:6, 651-653
CrossRef52
David J. A. Goldsmith, John Cunningham. (2011) Mineral metabolism and vitamin D in chronic kidney disease—more questions than answers. Nature Reviews Nephrology 7:6, 341-346
CrossRef53
J. Cunningham, J. Silver. (2011) CKD-MBD: comfort in the trough of the U. Nephrology Dialysis Transplantation 26:6, 1764-1766
CrossRef54
Tamara Isakova, Patricia Wahl, Gabriela S Vargas, Orlando M Gutiérrez, Julia Scialla, Huiliang Xie, Dina Appleby, Lisa Nessel, Keith Bellovich, Jing Chen, Lee Hamm, Crystal Gadegbeku, Edward Horwitz, Raymond R Townsend, Cheryl A M Anderson, James P Lash, Chi-yuan Hsu, Mary B Leonard, Myles Wolf. (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney International 79:12, 1370-1378
CrossRef55
Rukshana Shroff, Catherine Quinlan, Mark Mitsnefes. (2011) Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation?. Pediatric Nephrology 26:6, 853-865
CrossRef56
Poyyapakkam R. Srivaths, Stuart L. Goldstein, Douglas M. Silverstein, Rajesh Krishnamurthy, Eileen D. Brewer. (2011) Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatric Nephrology 26:6, 945-951
CrossRef57
J. Bacchetta, P. Cochat, I.B. Salusky. (2011) FGF23 et Klotho : les nouveaux incontournables du métabolisme phosphocalcique. Archives de Pédiatrie 18:6, 686-695
CrossRef58
O. M. Gutiérrez, W. R. Farwell, D. Kermah, E. N. Taylor. (2011) Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporosis International 22:6, 1745-1753
CrossRef59
Jason Moore, Charles R.V. Tomson, M. Tessa Savage, Richard Borrows, Charles J. Ferro. (2011) Serum phosphate and calcium concentrations are associated with reduced patient survival following kidney transplantation. Clinical Transplantation 25:3, 406-416
CrossRef60
Uri S. Alon. (2011) Clinical practice. European Journal of Pediatrics 170:5, 545-554
CrossRef61
Edward R. Smith, Martin L. Ford, Laurie A. Tomlinson, Gary Weaving, Bernard F. Rocks, Chakravarthi Rajkumar, Stephen G. Holt. (2011) Instability of fibroblast growth factor-23 (FGF-23): Implications for clinical studies. Clinica Chimica Acta 412:11-12, 1008-1011
CrossRef62
Nathalie Saidenberg-Kermanac’h, Leila Souabni, Virginie Prendki, Dominique Prie, Marie-Christophe Boissier. (2011) Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. Joint Bone Spine 78:3, 306-308
CrossRef63
Rukshana Shroff. (2011) Dysregulated mineral metabolism in children with chronic kidney disease. Current Opinion in Nephrology and Hypertension 20:3, 233-240
CrossRef64
Eric N. Taylor, Eric B. Rimm, Meir J. Stampfer, Gary C. Curhan. (2011) Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. American Heart Journal 161:5, 956-962
CrossRef65
Jason R. Stubbs, James B. Wetmore. (2011) Does it Matter How Parathyroid Hormone Levels are Suppressed in Secondary Hyperparathyroidism?. Seminars in Dialysis 24:3, 298-306
CrossRef66
T. Isakova, C. A. M. Anderson, M. B. Leonard, D. Xie, O. M. Gutierrez, L. K. Rosen, J. Theurer, K. Bellovich, S. P. Steigerwalt, I. Tang, A. H. Anderson, R. R. Townsend, J. He, H. I. Feldman, M. Wolf, . (2011) Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrology Dialysis Transplantation 26:4, 1258-1265
CrossRef67
K. Olgaard, E. Lewin, J. Silver. (2011) Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD. Nephrology Dialysis Transplantation 26:4, 1117-1119
CrossRef68
L Darryl Quarles. (2011) The bone and beyond: 'Dem bones' are made for more than walking. Nature Medicine 17:4, 428-430
CrossRef69
Majd AI Mirza, Magnus K Karlsson, Dan Mellström, Eric Orwoll, Claes Ohlsson, Östen Ljunggren, Tobias E Larsson. (2011) Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. Journal of Bone and Mineral Research 26:4, 857-864
CrossRef70
Harald Jüppner. (2011) Phosphate and FGF-23. Kidney International 79, S24-S27
CrossRef71
A. Kirkpantur, M. Balci, O. A. Gurbuz, B. Afsar, B. Canbakan, R. Akdemir, M. D. Ayli. (2011) Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrology Dialysis Transplantation 26:4, 1346-1354
CrossRef72
Jason R. Stubbs, Steve Egwuonwu. (2011) Is fibroblast growth factor 23 a harbinger of mortality in CKD?. Pediatric Nephrology
CrossRef73
MATTHEW J DAMASIEWICZ, NIGEL D TOUSSAINT, KEVAN R POLKINGHORNE. (2011) Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications. Nephrology 16:3, 261-268
CrossRef74
Jessica Kendrick, Bryan Kestenbaum, Michel Chonchol. (2011) Phosphate and Cardiovascular Disease. Advances in Chronic Kidney Disease 18:2, 113-119
CrossRef75
Orlando M. Gutiérrez, Tamara Isakova, Gwen Enfield, Myles Wolf. (2011) Impact of Poverty on Serum Phosphate Concentrations in the Third National Health and Nutrition Examination Survey. Journal of Renal Nutrition 21:2, 140-148
CrossRef76
Chung-Yi Cheng, Makoto Kuro-o, Mohammed S. Razzaque. (2011) Molecular Regulation of Phosphate Metabolism by Fibroblast Growth Factor-23–Klotho System. Advances in Chronic Kidney Disease 18:2, 91-97
CrossRef77
Keith A. Hruska, Suresh Mathew. (2011) The Roles of the Skeleton and Phosphorus in the CKD Mineral Bone Disorder. Advances in Chronic Kidney Disease 18:2, 98-104
CrossRef78
Clemens Bergwitz, Harald Jüppner. (2011) Phosphate Sensing. Advances in Chronic Kidney Disease 18:2, 132-144
CrossRef79
C. Drechsler, M. Verduijn, S. Pilz, F. W. Dekker, R. T. Krediet, E. Ritz, C. Wanner, E. W. Boeschoten, V. Brandenburg, . (2011) Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrology Dialysis Transplantation 26:3, 1024-1032
CrossRef80
Jerry Yee. (2011) Phosphate Enters the Syzygy. Advances in Chronic Kidney Disease 18:2, 55-56
CrossRef81
Judith Blaine, Edward J. Weinman, Rochelle Cunningham. (2011) The Regulation of Renal Phosphate Transport. Advances in Chronic Kidney Disease 18:2, 77-84
CrossRef82
T. Isakova, O. M. Gutierrez, K. Smith, M. Epstein, L. K. Keating, H. Juppner, M. Wolf. (2011) Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrology Dialysis Transplantation 26:2, 584-591
CrossRef83
Wacharee Seeherunvong, Myles Wolf. (2011) Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. Pediatric Transplantation 15:1, 37-46
CrossRef84
Makoto Kuro-o. (2011) Klotho and the Aging Process. The Korean Journal of Internal Medicine 26:2, 113
CrossRef85
MaryAnn Zhang, Raymond Hsu, Chi-yuan Hsu, Kristina Kordesch, Erica Nicasio, Alfredo Cortez, Ian McAlpine, Sandra Brady, Hanjing Zhuo, Kirsten N Kangelaris, John Stein, Carolyn S Calfee, Kathleen D Liu. (2011) FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series study. Annals of Intensive Care 1:1, 21
CrossRef86
Patrick H. Biggar, Orfeas Liangos, Holger Fey, Vincent M. Brandenburg, Markus Ketteler. (2011) Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug?. Pediatric Nephrology 26:1, 7-18
CrossRef87
Katherine Wesseling-Perry, Renata C Pereira, Shobha Sahney, Barbara Gales, He-Jing Wang, Robert Elashoff, Harald Jüppner, Isidro B Salusky. (2011) Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney International 79:1, 112-119
CrossRef88
Shigeo Negi. (2011) Nihon Toseki Igakkai Zasshi 44:1, 41-43
CrossRef89
Domenico Russo, Yuri Battaglia. (2011) Clinical Significance of FGF-23 in Patients with CKD. International Journal of Nephrology 2011, 1-5
CrossRef90
Yoko Takeda, Hirotaka Komaba, Shunsuke Goto, Hideki Fujii, Michio Umezu, Hirohito Hasegawa, Akira Fujimori, Masato Nishioka, Shinichi Nishi, Masafumi Fukagawa. (2011) Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis Patients. American Journal of Nephrology 33:5, 421-426
CrossRef91
Judith E. Adams. 2011. Radiology of Rickets and Osteomalacia. , 861-889.
CrossRef92
Richard Lee, Thomas J Weber. (2010) Disorders of phosphorus homeostasis. Current Opinion in Endocrinology, Diabetes and Obesity 17:6, 561-567
CrossRef93
O. M. Gutierrez, T. Isakova, K. Smith, M. Epstein, N. Patel, M. Wolf. (2010) Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. Nephrology Dialysis Transplantation 25:12, 3970-3977
CrossRef94
Sridevi Devaraj, Catherine Duncan-Staley, Ishwarlal Jialal. (2010) Evaluation of a Method for Fibroblast Growth Factor-23: A Novel Biomarker of Adverse Outcomes in Patients with Renal Disease. Metabolic Syndrome and Related Disorders 8:6, 477-482
CrossRef95
Fan Cheng, Philippa Hulley. (2010) The osteocyte—A novel endocrine regulator of body phosphate homeostasis. Maturitas 67:4, 327-338
CrossRef96
P.-A. Westerberg, O. Ljunggren, T. E. Larsson, J. Wadstrom, T. Linde. (2010) Fibroblast growth factor-23 and mineral metabolism after unilateral nephrectomy. Nephrology Dialysis Transplantation 25:12, 4068-4071
CrossRef97
S. Seiler, B. Reichart, D. Roth, E. Seibert, D. Fliser, G. H. Heine. (2010) FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrology Dialysis Transplantation 25:12, 3983-3989
CrossRef98
P. Manghat, W. D. Fraser, A. S. Wierzbicki, I. Fogelman, D. J. Goldsmith, G. Hampson. (2010) Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporosis International 21:11, 1853-1861
CrossRef99
Tamara Isakova, Myles S Wolf. (2010) FGF23 or PTH: which comes first in CKD ?. Kidney International 78:10, 947-949
CrossRef100
Prasad Devarajan. (2010) The Use of Targeted Biomarkers for Chronic Kidney Disease. Advances in Chronic Kidney Disease 17:6, 469-479
CrossRef101
Justin Silver, Tally Naveh-Many. (2010) FGF23 and the parathyroid glands. Pediatric Nephrology 25:11, 2241-2245
CrossRef102
Mahmut I Yilmaz, Alper Sonmez, Mutlu Saglam, Halil Yaman, Selim Kilic, Erkan Demirkaya, Tayfun Eyileten, Kayser Caglar, Yusuf Oguz, Abdulgaffar Vural, Mujdat Yenicesu, Carmine Zoccali. (2010) FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney International 78:7, 679-685
CrossRef103
Steven M Brunelli, Glenn M Chertow, Elizabeth D Ankers, Edmund G Lowrie, Ravi Thadhani. (2010) The Authors Reply:. Kidney International 78:7, 710-711
CrossRef104
Harald Jüppner, Myles Wolf, Isidro B. Salusky. (2010) FGF-23: More than a regulator of renal phosphate handling?. Journal of Bone and Mineral Research 25:10, 2091-2097
CrossRef105
R. Marsell, K. B. Jonsson. (2010) The phosphate regulating hormone fibroblast growth factor-23. Acta Physiologica 200:2, 97-106
CrossRef106
Mustafa BALCI, Alper KIRKPANTUR, Mutlu GULBAY, Oguz Alp GURBUZ. (2010) Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodialysis International 14:4, 425-432
CrossRef107
C. Drechsler, S. Pilz, B. Obermayer-Pietsch, M. Verduijn, A. Tomaschitz, V. Krane, K. Espe, F. Dekker, V. Brandenburg, W. Marz, E. Ritz, C. Wanner. (2010) Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. European Heart Journal 31:18, 2253-2261
CrossRef108
U. Benck. (2010) Koronarkalzifikation und Mortalität bei diabetischer Nephropathie. Der Nephrologe 5:5, 419-421
CrossRef109
Mehmet Kanbay, Baris Afsar, Paul Gusbeth-Tatomir, Adrian Covic. (2010) Arterial stiffness in dialysis patients: where are we now?. International Urology and Nephrology 42:3, 741-752
CrossRef110
H. Olauson, A. R. Qureshi, T. Miyamoto, P. Barany, O. Heimburger, B. Lindholm, P. Stenvinkel, T. E. Larsson. (2010) Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?. Nephrology Dialysis Transplantation 25:9, 3033-3038
CrossRef111
Kamyar Kalantar-Zadeh, Anuja Shah, Uyen Duong, Rulin C Hechter, Ramanath Dukkipati, Csaba P Kovesdy. (2010) Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney International 78, S10-S21
CrossRef112
V. M. Brandenburg, G. Schlieper, N. Heussen, S. Holzmann, B. Busch, P. Evenepoel, R. Vanholder, B. Meijers, N. Meert, W. J. Fassbender, J. Floege, W. Jahnen-Dechent, M. Ketteler. (2010) Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrology Dialysis Transplantation 25:8, 2672-2679
CrossRef113
Seiji Fukumoto. (2010) FGF23: Phosphate metabolism and beyond. IBMS BoneKEy 7:8, 268-278
CrossRef114
M. M. Nasrallah, A. R. El-Shehaby, M. M. Salem, N. A. Osman, E. El Sheikh, U. A. Sharaf El Din. (2010) Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrology Dialysis Transplantation 25:8, 2679-2685
CrossRef115
Kristina F Möller, Markus J Kemper. (2010) Pediatric nephrology today. Pediatric Health 4:4, 383-385
CrossRef116
Jessica RL Warsch, Myles Wolf, Clinton B Wright. (2010) Chronic kidney disease in patients with cognitive impairment: a marker of microvascular damage or an independent risk factor?. Aging Health 6:4, 423-427
CrossRef117
L. A. Szczech, D. B. Bregman, R. A. Harrington, D. Morris, A. Butcher, T. A. Koch, L. T. Goodnough, M. Wolf, J. E. Onken. (2010) Randomized Evaluation of efficacy and safety of ferric carboxymaltose in Patients with iron deficiency Anaemia and Impaired Renal function (REPAIR-IDA): rationale and study design. Nephrology Dialysis Transplantation 25:7, 2368-2375
CrossRef118
Orlando M. Gutiérrez, Myles Wolf. (2010) Dietary Phosphorus Restriction in Advanced Chronic Kidney Disease: Merits, Challenges, and Emerging Strategies. Seminars in Dialysis 23:4, 401-406
CrossRef119
S. Pilz, A. Tomaschitz, C. Drechsler, E. Ritz, B. O. Boehm, T. B. Grammer, W. Marz. (2010) Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. European Heart Journal 31:13, 1591-1598
CrossRef120
Jorge B Cannata-Andía, Natalia Carrillo-López, Manuel Naves-Díaz. (2010) Estrogens and bone disease in chronic kidney disease: role of FGF23. Current Opinion in Nephrology and Hypertension 19:4, 354-358
CrossRef121
Michael van Husen, Ann-Katrin Fischer, Anja Lehnhardt, Ilka Klaassen, Kristina Möller, Dirk-E Müller-Wiefel, Markus J Kemper. (2010) Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney International 78:2, 200-206
CrossRef122
Ishir Bhan, Anil Dubey, Myles Wolf. (2010) Diagnosis and Management of Mineral Metabolism in CKD. Journal of General Internal Medicine 25:7, 710-716
CrossRef123
Anna L Zisman, Myles Wolf. (2010) Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Current Opinion in Nephrology and Hypertension 19:4, 335-342
CrossRef124
Eijin Ashikaga, Hirokazu Honda, Hiroki Suzuki, Nozomu Hosaka, Yuki Hirai, Daisuke Sanada, Mari Nakamura, Hisako Nagai, Kei Matsumoto, Noriyuki Kato, Masanori Mukai, Makoto Watanabe, Keiko Takahashi, Kanji Shishido, Tadao Akizawa. (2010) Impact of Fibroblast Growth Factor 23 on Lipids and Atherosclerosis in Hemodialysis Patients. Therapeutic Apheresis and Dialysis 14:3, 315-322
CrossRef125
So-Youn Park, Kyung-Hwan Jeong, Ju-Young Moon, Sang-Ho Lee, Chun-Gyoo Ihm, Sang Youl Rhee, Jeong-Taek Woo, In-Hwan Oh, Tae-Won Lee. (2010) The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients. Clinical and Experimental Nephrology 14:3, 239-243
CrossRef126
Yi-Wen Chiu, Sharon G Adler, Matthew J Budoff, Junichiro Takasu, Jamila Ashai, Rajnish Mehrotra. (2010) Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney International 77:12, 1107-1114
CrossRef127
Mathias Voigt, Dagmar-Christiane Fischer, Max Rimpau, Wolfgang Schareck, Dieter Haffner. (2010) Fibroblast growth factor (FGF)-23 and fetuin-A in calcified carotid atheroma. Histopathology 56:6, 775-788
CrossRef128
T. E. Larsson. (2010) The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe?. Nephrology Dialysis Transplantation 25:5, 1376-1381
CrossRef129
Adrian Covic, Mehmet Kanbay, Luminita Voroneanu, Faruk Turgut, Dragomir N. Serban, Ionela Lacramioara Serban, David J. Goldsmith. (2010) Vascular calcification in chronic kidney disease. Clinical Science 119:3, 111-121
CrossRef130
Tonelli, Marcello, Pannu, Neesh, Manns, Braden, . (2010) Oral Phosphate Binders in Patients with Kidney Failure. New England Journal of Medicine 362:14, 1312-1324
Full Text131
Solenne Pelletier, Roland Chapurlat. (2010) Optimizing bone health in chronic kidney disease. Maturitas 65:4, 325-333
CrossRef132
Jyothsna Gattineni, Michel Baum. (2010) Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatric Nephrology 25:4, 591-601
CrossRef133
Jorge B. Cannata-Andía, Minerva Rodriguez-García, Pablo Román-García, Diego Tuñón-le Poultel, Francisco López-Hernández, Diego Rodríguez-Puyol. (2010) New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. Pediatric Nephrology 25:4, 609-616
CrossRef134
Emily G. Farrow, Kenneth E. White. (2010) Recent advances in renal phosphate handling. Nature Reviews Nephrology 6:4, 207-217
CrossRef135
Makoto Kuro-o. (2010) Overview of the FGF23-Klotho axis. Pediatric Nephrology 25:4, 583-590
CrossRef136
Bernhard Bielesz. (2010) Is Fibroblast Growth Factor-23 a novel marker for phosphate burden in chronic kidney disease with prognostic implications?. Wiener klinische Wochenschrift 122:7-8, 194-197
CrossRef137
Katherine Wesseling-Perry. (2010) FGF-23 in bone biology. Pediatric Nephrology 25:4, 603-608
CrossRef138
D. E. Leaf, M. Wolf, L. Stern. (2010) Elevated FGF-23 in a patient with rhabdomyolysis-induced acute kidney injury. Nephrology Dialysis Transplantation 25:4, 1335-1337
CrossRef139
Tejas Patel, David M. Charytan. (2010) Cardiovascular Complications in Diabetic Kidney Disease. Seminars in Dialysis 23:2, 169-177
CrossRef140
Elif Hindié, Paolo Zanotti-Fregonara, Pierre-Alexandre Just, Emile Sarfati, Didier Mellière, Marie-Elisabeth Toubert, Jean-Luc Moretti, Christian Jeanguillaume, Isabelle Keller, Pablo Ureña-Torres. (2010) Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism. European Journal of Nuclear Medicine and Molecular Imaging 37:3, 623-634
CrossRef141
J. H. Ix, M. G. Shlipak, C. L. Wassel, M. A. Whooley. (2010) Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrology Dialysis Transplantation 25:3, 993-997
CrossRef142
Lesley Rees, Rukshana C. Shroff. (2010) Phosphate binders in CKD: chalking out the differences. Pediatric Nephrology 25:3, 385-394
CrossRef143
Eli Sprecher. (2010) Familial Tumoral Calcinosis: From Characterization of a Rare Phenotype to the Pathogenesis of Ectopic Calcification. Journal of Investigative Dermatology 130:3, 652-660
CrossRef144
H Galitzer, I Z Ben-Dov, Justin Silver, Tally Naveh-Many. (2010) Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney International 77:3, 211-218
CrossRef145
Hirotaka Komaba, Masafumi Fukagawa. (2010) FGF23–parathyroid interaction: implications in chronic kidney disease. Kidney International 77:4, 292-298
CrossRef146
Abboud, Hanna, Henrich, William L., . (2010) Stage IV Chronic Kidney Disease. New England Journal of Medicine 362:1, 56-65
Full Text147
Kosaku Nitta. (2010) Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease. International Journal of Nephrology 2010, 1-7
CrossRef148
Keiichi Ozono. (2010) A bone-kidney axis: New concept. Nihon Shoni Jinzobyo Gakkai Zasshi 23:2, 189-194
CrossRef149
E. Lars Penne, Neelke C. van der Weerd, Marinus A. van den Dorpel, Muriel P.C. Grooteman, Renée Lévesque, Menso J. Nubé, Michiel L. Bots, Peter J. Blankestijn, Piet M. ter Wee. (2010) Short-term Effects of Online Hemodiafiltration on Phosphate Control: A Result From the Randomized Controlled Convective Transport Study (CONTRAST). American Journal of Kidney Diseases 55:1, 77-87
CrossRef150
Sarah Seiler, Gunnar H Heine, Danilo Fliser. (2009) Clinical relevance of FGF-23 in chronic kidney disease. Kidney International 76, S34-S42
CrossRef151
H. Wollanka, W. Weidenmaier, C. Giersig. (2009) NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrology Dialysis Transplantation 24:12, 3882-3884
CrossRef152
Majd A.I. Mirza, Anders Larsson, Håkan Melhus, Lars Lind, Tobias E. Larsson. (2009) Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207:2, 546-551
CrossRef153
Florian Kronenberg. (2009) Emerging risk factors and markers of chronic kidney disease progression. Nature Reviews Nephrology 5:12, 677-689
CrossRef154
M. Morena, A.-M. Dupuy, I. Jaussent, H. Vernhet, G. Gahide, K. Klouche, A.-S. Bargnoux, C. Delcourt, B. Canaud, J.-P. Cristol. (2009) A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrology Dialysis Transplantation 24:11, 3389-3397
CrossRef155
Myles Wolf. (2009) Fibroblast growth factor 23 and the future of phosphorus management. Current Opinion in Nephrology and Hypertension 18:6, 463-468
CrossRef156
Hirotaka Tanaka, Takayuki Hamano, Naohiko Fujii, Kodo Tomida, Isao Matsui, Satoshi Mikami, Yasuyuki Nagasawa, Takahito Ito, Toshiki Moriyama, Masaru Horio, Enyu Imai, Yoshitaka Isaka, Hiromi Rakugi. (2009) The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone 45:5, 949-955
CrossRef157
M. Shawkat Razzaque. (2009) The FGF23–Klotho axis: endocrine regulation of phosphate homeostasis. Nature Reviews Endocrinology 5:11, 611-619
CrossRef158
Tamara Isakova, Orlando M Gutiérrez, Myles Wolf. (2009) A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney International 76:7, 705-716
CrossRef159
M. A. I. Mirza, T. Hansen, L. Johansson, H. Ahlstrom, A. Larsson, L. Lind, T. E. Larsson. (2009) Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrology Dialysis Transplantation 24:10, 3125-3131
CrossRef160
G. Jean, J.-C. Terrat, T. Vanel, J.-M. Hurot, C. Lorriaux, B. Mayor, C. Chazot. (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrology Dialysis Transplantation 24:9, 2792-2796
CrossRef161
Emily G Farrow, Kenneth E White. (2009) Tumor-induced osteomalacia. Expert Review of Endocrinology & Metabolism 4:5, 435-442
CrossRef162
M. Ketteler, P. H. Biggar. (2009) As nature did not predict dialysis--what we can learn from FGF23 in end-stage renal disease?. Nephrology Dialysis Transplantation 24:9, 2618-2620
CrossRef163
Majd A.I. Mirza, Anders Larsson, Lars Lind, Tobias E. Larsson. (2009) Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205:2, 385-390
CrossRef164
H. Eddington, J. G. Heaf. (2009) Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients. NDT Plus 2:4, 267-272
CrossRef165
M. Cozzolino. (2009) The role of FGF-23 in CKD patients still needs to be clarified. Nephrology Dialysis Transplantation 24:8, 2605-2605
CrossRef166
(2009) Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities. Kidney International 76, S22-S49
CrossRef167
(2009) Journal Club. Kidney International 76:4, 357-358
CrossRef168
Jian Q Feng, Ling Ye, Susan Schiavi. (2009) Do osteocytes contribute to phosphate homeostasis?. Current Opinion in Nephrology and Hypertension 18:4, 285-291
CrossRef169
Charles P. McKay, Anthony Portale. (2009) Emerging Topics in Pediatric Bone and Mineral Disorders 2008. Seminars in Nephrology 29:4, 370-378
CrossRef170
M. Kuro-o. (2009) Klotho in chronic kidney disease--What's new?. Nephrology Dialysis Transplantation 24:6, 1705-1708
CrossRef171
Mario Cozzolino, Maurizio Gallieni, Sabina Pasho, Giuditta Fallabrino, Paola Ciceri, Elisa Maria Volpi, Laura Olivi, Diego Brancaccio. (2009) Management of Secondary Hyperparathyroidism in the Elderly Patient with Chronic Kidney Disease. Drugs & Aging 26:6, 457-468
CrossRef172
Mohga M El-Abbadi, Ashwini S Pai, Elizabeth M Leaf, Hsueh-Ying Yang, Bryan A Bartley, Krystle K Quan, Carly M Ingalls, Hung Wei Liao, Cecilia M Giachelli. (2009) Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney International 75:12, 1297-1307
CrossRef173
Dominique Prié, Pablo Ureña Torres, Gérard Friedlander. (2009) Latest findings in phosphate homeostasis. Kidney International 75:9, 882-889
CrossRef174
Alexander Kapustin, Catherine M Shanahan. (2009) Targeting vascular calcification: softening-up a hard target. Current Opinion in Pharmacology 9:2, 84-89
CrossRef175
Keith A. Hruska, Suresh Mathew, Richard J. Lund, Imran Memon, Georges Saab. (2009) The Pathogenesis of Vascular Calcification in the Chronic Kidney Disease Mineral Bone Disorder: The Links Between Bone and the Vasculature. Seminars in Nephrology 29:2, 156-165
CrossRef176
Andrew Beenken, Moosa Mohammadi. (2009) The FGF family: biology, pathophysiology and therapy. Nature Reviews Drug Discovery 8:3, 235-253
CrossRef177
Tejas V. Patel, Ajay K. Singh. (2009) Role of Vitamin D in Chronic Kidney Disease. Seminars in Nephrology 29:2, 113-121
CrossRef178
Tejas V. Patel, Ajay K. Singh. (2009) Kidney Disease Outcomes Quality Initiative Guidelines for Bone and Mineral Metabolism: Emerging Questions. Seminars in Nephrology 29:2, 105-112
CrossRef179
Michal Chmielewski, Juan Jesus Carrero, Peter Stenvinkel, Bengt Lindholm. (2009) Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. Current Opinion in Lipidology 20:1, 3-9
CrossRef180
Richard A. Sherman. (2009) Briefly noted. Seminars in Dialysis 22:1, 105-106
CrossRef181
James B Wetmore, L Darryl Quarles. (2009) Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?. Nature Clinical Practice Nephrology 5:1, 24-33
CrossRef182
C. Zoccali. (2008) FGF-23 in dialysis patients: ready for prime time?. Nephrology Dialysis Transplantation 24:4, 1078-1081
CrossRef183
L. Darryl Quarles. (2008) Endocrine functions of bone in mineral metabolism regulation. Journal of Clinical Investigation 118:12, 3820-3828
CrossRef184
(2008) FGF-23: a novel predictor of mortality in patients on hemodialysis?. Nature Clinical Practice Nephrology 4:11, 585-585
CrossRef185
(2008) Journal Club. Kidney International 74:9, 1107-1108
CrossRef186
Serge Ferrari, Ego Seeman, Hong-Wen Deng, David G Little, Toshio Matsumoto. (2008) Clinical and basic research papers – September 2008. IBMS BoneKEy 5:9, 302-307
CrossRef187
Hsu, Chi-yuan, . (2008) FGF-23 and Outcomes Research — When Physiology Meets Epidemiology. New England Journal of Medicine 359:6, 640-642
Full Text188
M. S. Razzaque. (2008) Does FGF23 toxicity influence the outcome of chronic kidney disease?. Nephrology Dialysis Transplantation 24:1, 4-7
CrossRef189
Un Sil Jeon. (2008) Kidney and Calcium Homeostasis. Electrolyte & Blood Pressure 6:2, 68
CrossRef
